The most frequently observed EGFR mutations in NSCLC patients, together accounting for over 90% of oncogenic EGFR aberrations in this cancer2–4, are in exons 19 (45%4) and 21 (46%4). This evidence concerns the gene EGFR and non-small cell lung carcinoma.